.png)
.png)
Latest news from BIA
BIA responds to House of Commons Health and Social Care Committee report on antimicrobial resistance
The BioIndustry Association (BIA) has responded to the House of Commons Health and Social Care Committee report on antimicrobial resistance released today.
Excellent science, attracting global talent and investment, creating jobs, growth and delivering the therapies of the future – the state of the UK bioscience ecosystem in 2018
Commenting on the state of the UK life sciences ecosystem in a keynote address to the Bioindustry Association (BIA) UK Bioscience Forum in London BIA CEO Steve Bates OBE, will say: “The UK life sciences ecosystem is in a fantastic place. I see innovation, opportunity and collaboration everywhere. We are in an era of profound scientific opportunity.” The opening address will cover key issues that are currently having an impact on the UK bioscience ecosystem including government funding, Brexit, R&D development, the NHS and the future of the European Medicines Agency (EMA).
BIA launches videos and explainer documents celebrating UK bioscience and revealing the cutting-edge R&D taking place in biotech companies around the UK
The UK BioIndustry Association (BIA) has today launched a series of four explainer booklets and five videos that celebrate the fantastic work taking place in UK bioscience companies to create innovative new drugs and treatments for patients.
Scientist.com Partners with UK-based BioIndustry Association (BIA)
Global outsourcing leader Scientist.com to deliver Faster ScienceTM to BIA members throughout the UK SAN DIEGO & LONDON, DATE (BUSINESS WIRE) - Scientist.com, the world’s largest marketplace for outsourced scientific services, today announced a partnership with the BioIndustry Association (BIA), the UK’s national trade association for innovative bioscience enterprises. The partnership will allow BIA members to access the Scientist.com marketplace, connect with global experts and purchase custom research services required for drug R&D.
Locate Therapeutics changes name and receive £0.5 million investment from Mercia
Locate Bio Limited (“Locate” or “Company”) a specialist regenerative medicine company based in Nottingham, UK, has changed its name from Locate Therapeutics Limited and received a new direct investment of £0.5 million from Mercia Technologies PLC (AIM: MERC) (“Mercia”).
Synpromics Promoter Technology Moves Closer to the Clinic
Synpromics announces positive data presented today by uniQure at the European Society of Gene and Cell Therapy conference. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.
Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award
Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. These prestigious OBN awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.
Synpromics Unveils Next Generation Liver Selective and Tunable Promoter Platform
Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.
CEO Update | Monday 22 October
New explainer videos, new R+D tax guide, Commons’ Select committee on AMR and new Scientist.com deal It’s great to celebrate and explain our sector. Last week we launched our Celebrating UK Bioscience videos and re-vamped our Strategic Technologies webpage with fantastic new content. We generated just under half a million unique impressions on Twitter in 3 days, and I’d like you to share these resources with your network to drive better understanding of our sector and what it does.
Life Sciences Industrial Strategy & Sector Deal Newsletter | October 2018
Welcome to the October edition of the Life Sciences Industrial Strategy & Sector Deal Newsletter. Here you will find an update on how we are progressing with the implementation of phase 1 of the Life Sciences Sector Deal as well as our upcoming priorities and engagement opportunities.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
